[Public health costs of influenza in Germany 1996- a cost-of-illness analysis].
Identifieur interne : 000565 ( Main/Exploration ); précédent : 000564; suivant : 000566[Public health costs of influenza in Germany 1996- a cost-of-illness analysis].
Auteurs : T. Szucs [Suisse] ; M. Behrens ; T. VolmerSource :
- Medizinische Klinik (Munich, Germany : 1983) [ 0723-5003 ] ; 2001.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Allemagne (épidémiologie), Analyse coût-bénéfice (MeSH), Antibactériens (usage thérapeutique), Antibactériens (économie), Antiviraux (usage thérapeutique), Antiviraux (économie), Coûts indirects de la maladie (MeSH), Enfant (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (économie), Grippe humaine (épidémiologie), Guides de bonnes pratiques cliniques comme sujet (MeSH), Humains (MeSH), Programmes de vaccination (statistiques et données numériques), Programmes de vaccination (économie), Épidémies de maladies (économie).
- MESH :
- prévention et contrôle : Grippe humaine.
- statistiques et données numériques : Programmes de vaccination.
- usage thérapeutique : Antibactériens, Antiviraux.
- économie : Antibactériens, Antiviraux, Grippe humaine, Programmes de vaccination, Épidémies de maladies.
- épidémiologie : Allemagne, Grippe humaine.
- Adulte d'âge moyen, Analyse coût-bénéfice, Coûts indirects de la maladie, Enfant, Guides de bonnes pratiques cliniques comme sujet, Humains.
English descriptors
- KwdEn :
- Anti-Bacterial Agents (economics), Anti-Bacterial Agents (therapeutic use), Antiviral Agents (economics), Antiviral Agents (therapeutic use), Child (MeSH), Cost of Illness (MeSH), Cost-Benefit Analysis (MeSH), Disease Outbreaks (economics), Germany (epidemiology), Humans (MeSH), Immunization Programs (economics), Immunization Programs (statistics & numerical data), Influenza, Human (economics), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Middle Aged (MeSH), Practice Guidelines as Topic (MeSH).
- MESH :
- chemical , economics : Anti-Bacterial Agents, Antiviral Agents.
- chemical , therapeutic use : Anti-Bacterial Agents, Antiviral Agents.
- economics : Disease Outbreaks, Immunization Programs, Influenza, Human.
- epidemiology : Germany, Influenza, Human.
- prevention & control : Influenza, Human.
- statistics & numerical data : Immunization Programs.
- Child, Cost of Illness, Cost-Benefit Analysis, Humans, Middle Aged, Practice Guidelines as Topic.
Abstract
Influenza is often seen as an unproblematic and self-limiting disease despite putting a high burden on patients as well as being of high socio-economic relevance to societies. This analysis aims to visualize that influenza deserves a rise in attention especially because of its socio-economic relevance, based on a transparent methodology. This analysis investigates the costs caused by influenza in Germany in 1996. The analysis is based on a costs model that takes in official aggregated statistical and publicly available data. A top-down approach based on the ICD-9 Code 487 is used. The costs of influenza in 1996 came to nearly DM 5 billion. Only a small proportion of this was due to direct treatment costs (DM 0.6 billion). The direct costs are made up of 304 million DM (52.8%) for ambulatory care, 214 million DM (37.1%) for prescription-only and OTC medication, and 58 million DM (10.1%) for inpatient treatment including rehabilitation measures. The bulk of the indirect costs, some DM 4.4 billion (99.5%), was due to unfitness for work, whereas only about 21 million DM (0.5%) was accounted for by occupational disability and deaths. On the basis of an estimated 4 million cases of influenza in 1996 (no epidemics), the costs work out at about 1,237 DM per patient per year. In the event of an epidemic, the German economy would be faced with correspondingly higher costs of over DM 10.5 billion. Effective prevention and treatment strategies such as better pre-season vaccination rates, early diagnosis and effective antiviral therapy can help to reduce this financial burden.
DOI: 10.1007/pl00002180
PubMed: 11253284
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Public health costs of influenza in Germany 1996- a cost-of-illness analysis].</title><author><name sortKey="Szucs, T" sort="Szucs, T" uniqKey="Szucs T" first="T" last="Szucs">T. Szucs</name><affiliation wicri:level="1"><nlm:affiliation>Abteilung für Medizinökonomie Universitätshospital Rämistrasse 100 CH-8000 Zürich. Thomas.Szucs@vdi.usz.ch</nlm:affiliation><country wicri:rule="url">Suisse</country></affiliation></author><author><name sortKey="Behrens, M" sort="Behrens, M" uniqKey="Behrens M" first="M" last="Behrens">M. Behrens</name></author><author><name sortKey="Volmer, T" sort="Volmer, T" uniqKey="Volmer T" first="T" last="Volmer">T. Volmer</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2001">2001</date><idno type="RBID">pubmed:11253284</idno><idno type="pmid">11253284</idno><idno type="doi">10.1007/pl00002180</idno><idno type="wicri:Area/Main/Corpus">000572</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000572</idno><idno type="wicri:Area/Main/Curation">000572</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000572</idno><idno type="wicri:Area/Main/Exploration">000572</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Public health costs of influenza in Germany 1996- a cost-of-illness analysis].</title><author><name sortKey="Szucs, T" sort="Szucs, T" uniqKey="Szucs T" first="T" last="Szucs">T. Szucs</name><affiliation wicri:level="1"><nlm:affiliation>Abteilung für Medizinökonomie Universitätshospital Rämistrasse 100 CH-8000 Zürich. Thomas.Szucs@vdi.usz.ch</nlm:affiliation><country wicri:rule="url">Suisse</country></affiliation></author><author><name sortKey="Behrens, M" sort="Behrens, M" uniqKey="Behrens M" first="M" last="Behrens">M. Behrens</name></author><author><name sortKey="Volmer, T" sort="Volmer, T" uniqKey="Volmer T" first="T" last="Volmer">T. Volmer</name></author></analytic><series><title level="j">Medizinische Klinik (Munich, Germany : 1983)</title><idno type="ISSN">0723-5003</idno><imprint><date when="2001" type="published">2001</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-Bacterial Agents (economics)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antiviral Agents (economics)</term><term>Antiviral Agents (therapeutic use)</term><term>Child (MeSH)</term><term>Cost of Illness (MeSH)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Disease Outbreaks (economics)</term><term>Germany (epidemiology)</term><term>Humans (MeSH)</term><term>Immunization Programs (economics)</term><term>Immunization Programs (statistics & numerical data)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Middle Aged (MeSH)</term><term>Practice Guidelines as Topic (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Allemagne (épidémiologie)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Antibactériens (usage thérapeutique)</term><term>Antibactériens (économie)</term><term>Antiviraux (usage thérapeutique)</term><term>Antiviraux (économie)</term><term>Coûts indirects de la maladie (MeSH)</term><term>Enfant (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (économie)</term><term>Grippe humaine (épidémiologie)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Humains (MeSH)</term><term>Programmes de vaccination (statistiques et données numériques)</term><term>Programmes de vaccination (économie)</term><term>Épidémies de maladies (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Disease Outbreaks</term><term>Immunization Programs</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Germany</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Immunization Programs</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Programmes de vaccination</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Antibactériens</term><term>Antiviraux</term><term>Grippe humaine</term><term>Programmes de vaccination</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Allemagne</term><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Cost of Illness</term><term>Cost-Benefit Analysis</term><term>Humans</term><term>Middle Aged</term><term>Practice Guidelines as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Coûts indirects de la maladie</term><term>Enfant</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza is often seen as an unproblematic and self-limiting disease despite putting a high burden on patients as well as being of high socio-economic relevance to societies. This analysis aims to visualize that influenza deserves a rise in attention especially because of its socio-economic relevance, based on a transparent methodology. This analysis investigates the costs caused by influenza in Germany in 1996. The analysis is based on a costs model that takes in official aggregated statistical and publicly available data. A top-down approach based on the ICD-9 Code 487 is used. The costs of influenza in 1996 came to nearly DM 5 billion. Only a small proportion of this was due to direct treatment costs (DM 0.6 billion). The direct costs are made up of 304 million DM (52.8%) for ambulatory care, 214 million DM (37.1%) for prescription-only and OTC medication, and 58 million DM (10.1%) for inpatient treatment including rehabilitation measures. The bulk of the indirect costs, some DM 4.4 billion (99.5%), was due to unfitness for work, whereas only about 21 million DM (0.5%) was accounted for by occupational disability and deaths. On the basis of an estimated 4 million cases of influenza in 1996 (no epidemics), the costs work out at about 1,237 DM per patient per year. In the event of an epidemic, the German economy would be faced with correspondingly higher costs of over DM 10.5 billion. Effective prevention and treatment strategies such as better pre-season vaccination rates, early diagnosis and effective antiviral therapy can help to reduce this financial burden.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11253284</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0723-5003</ISSN><JournalIssue CitedMedium="Print"><Volume>96</Volume><Issue>2</Issue><PubDate><Year>2001</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Medizinische Klinik (Munich, Germany : 1983)</Title><ISOAbbreviation>Med. Klin. (Munich)</ISOAbbreviation></Journal><ArticleTitle>[Public health costs of influenza in Germany 1996- a cost-of-illness analysis].</ArticleTitle><Pagination><MedlinePgn>63-70</MedlinePgn></Pagination><Abstract><AbstractText>Influenza is often seen as an unproblematic and self-limiting disease despite putting a high burden on patients as well as being of high socio-economic relevance to societies. This analysis aims to visualize that influenza deserves a rise in attention especially because of its socio-economic relevance, based on a transparent methodology. This analysis investigates the costs caused by influenza in Germany in 1996. The analysis is based on a costs model that takes in official aggregated statistical and publicly available data. A top-down approach based on the ICD-9 Code 487 is used. The costs of influenza in 1996 came to nearly DM 5 billion. Only a small proportion of this was due to direct treatment costs (DM 0.6 billion). The direct costs are made up of 304 million DM (52.8%) for ambulatory care, 214 million DM (37.1%) for prescription-only and OTC medication, and 58 million DM (10.1%) for inpatient treatment including rehabilitation measures. The bulk of the indirect costs, some DM 4.4 billion (99.5%), was due to unfitness for work, whereas only about 21 million DM (0.5%) was accounted for by occupational disability and deaths. On the basis of an estimated 4 million cases of influenza in 1996 (no epidemics), the costs work out at about 1,237 DM per patient per year. In the event of an epidemic, the German economy would be faced with correspondingly higher costs of over DM 10.5 billion. Effective prevention and treatment strategies such as better pre-season vaccination rates, early diagnosis and effective antiviral therapy can help to reduce this financial burden.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Szucs</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Abteilung für Medizinökonomie Universitätshospital Rämistrasse 100 CH-8000 Zürich. Thomas.Szucs@vdi.usz.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Behrens</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Volmer</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Volkswirtschaftliche Kosten der Influenza 1996. Eine Krankheitskostenstudie.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Med Klin (Munich)</MedlineTA><NlmUniqueID>8303501</NlmUniqueID><ISSNLinking>0723-5003</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>21</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>20</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11253284</ArticleId><ArticleId IdType="doi">10.1007/pl00002180</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Suisse</li></country></list><tree><noCountry><name sortKey="Behrens, M" sort="Behrens, M" uniqKey="Behrens M" first="M" last="Behrens">M. Behrens</name><name sortKey="Volmer, T" sort="Volmer, T" uniqKey="Volmer T" first="T" last="Volmer">T. Volmer</name></noCountry><country name="Suisse"><noRegion><name sortKey="Szucs, T" sort="Szucs, T" uniqKey="Szucs T" first="T" last="Szucs">T. Szucs</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000565 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000565 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:11253284
|texte= [Public health costs of influenza in Germany 1996- a cost-of-illness analysis].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:11253284" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |